资源类型：
会议/期刊
收录情况：
◇ SCIE
文章类型：
会议摘要
作者：
Zhou, Q.[1]
*
;
Wu, Y-L.[2]
;
Wu, L.[3]
;
Zhang, Y.[4,11]
;
Ni, S.[4]
;
Liu, A.[5]
;
Li, J.[6]
;
Lin, G.[7]
;
Cui, J.[8]
;
Yao, W.[9]
;
Sun, J-M.[10]
;
Zhang, Y.[4,11]
;
Su, H.[12]
;
Li, Y.[13]
;
Yamamoto, N.[14]
;
Kuboki, Y.[15]
;
Han, S-W.[16]
;
Wang, Z.[17]
;
Qiu, F.[17]
;
Yang, L.[17]
;
机构：
[1]Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China
广东省人民医院
[2]Hunan Canc Hosp, Thorac Med Oncol Dept, Changsha, Peoples R China
[3]Shandong Canc Hosp & Inst, Phase Clin Res Ctr 1, Jinan, Peoples R China
[4]Nanchang Univ, Dept Oncol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
[5]Nanchang Univ, Ctr Drug Clin Res, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
[6]Fujian Canc Hosp, Dept Chest Oncol, Fuzhou, Peoples R China
[7]Fujian Med Univ Canc Hosp, Fuzhou, Peoples R China
[8]First Hosp Jilin Univ, Dept Oncol, Changchun, Peoples R China
[9]UESTC, Sichuan Canc Hosp & Inst, Dept Med Oncol, Affiliated Canc Hosp,Sch Med, Chengdu, Peoples R China
四川省肿瘤医院
[10]Sungkyunkwan Univ, Samsung Med Ctr SMC, Med Dept, Sch Med, Seoul, South Korea
[11]Sichuan Univ, Canc Ctr, Dept Thorac Oncol, West China Hosp, Chengdu, Peoples R China
四川大学华西医院
[12]Air Force Med Univ, Dept Oncol, Affiliated Hosp 2, Tangdu Hosp, Xian, Peoples R China
[13]Chongqing Univ Canc Hosp, Phase Clin Trial Ward 1, Chongqing, Peoples R China
[14]NCCH Natl Canc Ctr Hosp Tsukiji Campus, Dev Therapeut Dept, Chuo Ku, Tokyo, Japan
[15]Natl Canc Ctr Hosp East, Expt Therapeut & GI Oncol Dept, Kashiwa, Chiba, Japan
[16]Seoul Natl Univ Hosp, Dept Hematol Oncol, Seoul, South Korea
[17]Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China
ISSN：
0923-7534
基金：
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
被引次数：
1
WOS：
WOS:001326612900636
中科院(CAS)分区：
出版当年[2025]版：
大类
|
1 区
医学
小类
|
1 区
肿瘤学
最新[2025]版：
大类
|
1 区
医学
小类
|
1 区
肿瘤学
影响因子：
56.7
最新[2023版]
38.2
最新五年平均
56.7
出版当年[2023版]
0
出版当年五年平均
56.7
出版前一年[2023版]
第一作者：
Zhou, Q.
第一作者机构：
[1]Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Zhou Q.,Wu Y-L.,Wu L.,et al.Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC[J].ANNALS OF ONCOLOGY.2024,35:S509-S509.doi:10.1016/j.annonc.2024.08.709.
APA：
Zhou, Q.,Wu, Y-L.,Wu, L.,Zhang, Y.,Ni, S....&Yang, L..(2024).Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC.ANNALS OF ONCOLOGY,35,
MLA：
Zhou, Q.,et al."Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC".ANNALS OF ONCOLOGY 35.(2024):S509-S509
医学